BDF Gestion Sells 4,389 Shares of Royalty Pharma plc (NASDAQ:RPRX)

BDF Gestion decreased its stake in Royalty Pharma plc (NASDAQ:RPRX) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,792 shares of the biopharmaceutical company’s stock after selling 4,389 shares during the period. BDF Gestion’s holdings in Royalty Pharma were worth $862,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Brooklyn Investment Group raised its position in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 876 shares in the last quarter. Blue Trust Inc. increased its position in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 943 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 997 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Royalty Pharma in the 3rd quarter worth approximately $61,000. Finally, GAMMA Investing LLC boosted its stake in Royalty Pharma by 31.4% in the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 590 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $31.59 on Friday. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $32.21. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average of $27.13 and a 200-day moving average of $27.47. The firm has a market cap of $18.61 billion, a P/E ratio of 16.37 and a beta of 0.47.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be paid a $0.22 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.79%. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Analyst Ratings Changes

RPRX has been the subject of a number of recent research reports. Citigroup lowered their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma has an average rating of “Buy” and an average price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.